Through the material transfer agreement –MTA- the veterinarian company will test a vaccine produced by the Bionaturis´ FLYLIFE.
It is a strategic milestone of the Spanish Biotech company for the development and achievement of its business plan.
The agreement involves an exclusive out-license option for the big laboratory and give access to Bionaturis to an international market of large numbers.

Bionaturis (BNT-MAB) has signed a strategic Material Transfer Agreement (MTA) with a multinational veterinarian company to evaluate the efficacy and safety of a vaccine produced by means of Flylife system. The multinational will execute in vivo exploratory trials of the vaccine over the intended animal of protection. The agreement also includes options of exclusive in-licensing rights for the veterinarian company.
According to Victor Infante -CEO of Bionaturis- statements “this contract represents a major milestone for out-licensing our current portfolio (BNTs) as well as our Flylife system. The confidence of multinational partners is key to our business model. This agreement is a strategic step for our growth and we will announce other similar in the forthcoming months.”